DiagnoCure Inc. announced earnings results for the third quarter ended July 31, 2013. Total revenues for the third quarter 2013 were $189,585 compared with $709,754 for the same period of 2012. This decrease of $520,169 is attributable to the termination, on January 11, 2013 of the development and license agreements signed in June 2011 with Signal Genetics.

Net loss (before stock-based compensation, depreciation and amortization) of $351,753 compared with $320,179 for the same period a year ago. Net loss and comprehensive loss was $595,262 or $0.01 per basic and diluted share compared with $606,049 or $0.01 per basic and diluted share for the same period a year ago.